Get the Stockscreener App
0.88
0.95%
-0.0084
After Hours:
.88
Inflarx N V stock is traded at $0.88, with a volume of 184.44K.
It is down -0.95% in the last 24 hours and up +9.67% over the past month.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
See More
Previous Close:
$0.8884
Open:
$0.92
24h Volume:
184.44K
Relative Volume:
0.41
Market Cap:
$59.08M
Revenue:
-
Net Income/Loss:
$-46.12M
P/E Ratio:
-1.0183
EPS:
-0.8642
Net Cash Flow:
$-41.02M
1W Performance:
+0.69%
1M Performance:
+9.67%
6M Performance:
-64.80%
1Y Performance:
-36.23%
1-Day Range:
$0.8605
$0.9242
1-Week Range:
$0.836
$0.95
52-Week Range:
$0.7113
$2.815
Inflarx N V Stock (IFRX) Company Profile
Compare IFRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IFRX
Inflarx N V
|
0.88 | 60.19M | 0 | -46.12M | -41.02M | -0.8642 |
|
VRTX
Vertex Pharmaceuticals Inc
|
374.98 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.90 | 60.58B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
418.91 | 54.99B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
674.90 | 42.25B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.23 | 32.93B | 3.81B | -644.79M | -669.77M | -6.24 |
Inflarx N V Stock (IFRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-29-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-05-23 | Upgrade | Guggenheim | Neutral → Buy |
| Feb-28-22 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-28-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-11-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-06-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Oct-08-20 | Initiated | H.C. Wainwright | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Apr-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-05-19 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jun-05-19 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-05-19 | Downgrade | JP Morgan | Overweight → Underweight |
| Jun-05-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-05-19 | Downgrade | SunTrust | Buy → Hold |
| Jan-29-19 | Initiated | Robert W. Baird | Outperform |
| Dec-10-18 | Initiated | Credit Suisse | Outperform |
| Jul-13-18 | Initiated | BMO Capital Markets | Outperform |
| Jun-28-18 | Initiated | Raymond James | Outperform |
| Jun-28-18 | Initiated | SunTrust | Buy |
| Feb-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Inflarx N V Stock (IFRX) Latest News
Sector ETF performance correlation with InflaRx N.V.High Return Idea With Technical Filter - Newser
Is it time to cut losses on InflaRx N.V.Secure Entry Point Finder with Analysis - Newser
Sentiment analysis tools applied to InflaRx N.V.Real Time Alert System for Market Moves - Newser
Understanding InflaRx N.V.’s price movementRapid Trade Forecast Based on Indicators - Newser
How high can InflaRx N.V. stock goVolume Confirmed Setup with Entry Confidence - Newser
Tools to assess InflaRx N.V.’s risk profileFree Profit Target Stock Opportunity Monitor - Newser
What to do if you’re stuck in InflaRx N.V.Free Swing Trading Plan With Smart Signals - Newser
Applying chart zones and confluence areas to InflaRx N.V.Real Time Screener for Growth Trades - Newser
What MACD signals say about InflaRx N.V.Free Beginner Friendly Stock Selection Guide - Newser
What are analysts’ price targets for InflaRx N.V. in the next 12 monthsUnlock powerful portfolio management tools - Jammu Links News
How does InflaRx N.V. compare to its industry peersMaximize portfolio returns with smart trading - Jammu Links News
What drives InflaRx N.V. stock priceFree Stock Market Return Analysis - Jammu Links News
Should I hold or sell InflaRx N.V. stock in 2025Invest smarter with expert trading signals - Jammu Links News
What is InflaRx N.V. company’s growth strategyTransform your portfolio with high-yield stocks - Jammu Links News
What are the latest earnings results for InflaRx N.V.Consistent high-performance stocks - Jammu Links News
Key resistance and support levels for InflaRx N.V.Free Fundamental Winners With Safe Entry Plan - Newser
Applying Elliott Wave Theory to InflaRx N.V.Free Scalable Portfolio Growth Suggestions - Newser
How does InflaRx N.V. generate profit in a changing economyConsistently superior profits - Jammu Links News
How many analysts rate InflaRx N.V. as a “Buy”Exceptional ROI - Jammu Links News
When is InflaRx N.V. stock expected to show significant growthMaximize portfolio returns with smart trading - Jammu Links News
Is InflaRx N.V. Stock a Good Fit for Conservative InvestorsEarnings Based Stock Performance Forecast - Newser
InflaRx (IFRX) to Release Earnings on Thursday - Defense World
Why InflaRx N.V. stock attracts strong analyst attentionGrowth Projection Summary for Long-Term Investors - Newser
How volatile is InflaRx N.V. stock compared to the marketBeginner Investor Report With Low Risk - Jammu Links News
Sentiment Turns Positive on InflaRx N.V. — Reversal AheadLong Hold Safe Return Strategy Reviewed - metal.it
InflaRx N.V. stock momentum explainedFree Low Risk Buy Zone Opportunity Watch - Newser
Does InflaRx N.V. stock perform well during market downturnsReal Time Tracker With High Returns - Jammu Links News
InflaRx receives Nasdaq notice for non-compliance with minimum bid price rule - MSN
InflaRx (NASDAQ:IFRX) Trading 2.8% Higher – What’s Next? - Defense World
InflaRx to Report Second Quarter 2025 Results on August 7, 2025 - GlobeNewswire
InflaRx Q2 Earnings Coming August 7: Anti-Inflammatory Drug Developer's Latest Financial Picture - Stock Titan
Top Risks to Consider Before Buying InflaRx N.V. Stock7-Day Equity Return Range Forecast Model - Newser
What makes InflaRx N.V. stock price move sharplyBreakout Stock Opportunities with Low Drawdown - Newser
Inflarx N V Stock (IFRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):